Cancer has traditionally been viewed as a high-cost but time‑limited event. That assumption no longer holds. As more cancers are diagnosed in younger, working‑age employees, cancer is increasingly becoming a long‑horizon condition, extending engagement with the health care system well beyond an initial episode of care.
For employers, this shift carries important implications. Earlier cancer onset means costs accrue not just during treatment, but across years of follow‑up, survivorship care, and, in some cases, recurrence. The result is greater cumulative cost exposure over time, often within employer-sponsored health plans, and a growing need to rethink how benefits and care strategies are designed.
Younger employees face higher average cancer care costs—and longer exposure
Findings from Evernorth Research Institute’s Health Care in Focus report on oncology shows that from 2020 to 2024, mean total cost of care per person per year (PPPY) for new cancer cases increased from $34,745 to $48,177 for Gen Z, and from $26,667 to $37,774 for millennials, compared to from $25,382 to $31,960 for Gen X and from $21,210 to $29,724 for baby boomers, as they transition out of employer-sponsored coverage.
Although younger employees represent a smaller share of overall cancer diagnoses, two factors help explain their higher average costs and long-term impact.
Cancer type mix plays a significant role
Younger employees are disproportionately affected by certain cancers associated with elevated annual spending. Cancers of the brain and central nervous system and lymphomas, for example, are among the most expensive, with PPPY total costs exceeding $200,000.1While these cancers are less common overall, younger employees’ over‑representation in these high‑cost categories increases both average spend and long‑term exposure.
Time magnifies cost of cancer care
A diagnosis earlier in life extends the care horizon. Younger employees may require years of follow‑up imaging, specialty drugs, late‑effect management, and survivorship care. Even if annual costs moderate over time, the cumulative financial impact can be substantial.
For employers, this means that a younger workforce does not necessarily equate to lower cancer-related spend. In many cases, early-onset cancer shifts financial exposure forward and extends it across many years of coverage.
The workforce impact goes beyond medical claims
Cancer diagnosed during prime working years often intersects with career development, family responsibilities, and financial obligations. As a result, early-onset cancer increases demand for services that may fall outside traditional cancer benefit designs, including:
- Fertility preservation and family‑planning support
- Mental and behavioral health services
- Long‑term rehabilitation for physical or cognitive effects
- Care navigation across complex treatment pathways
- Return‑to‑work planning and workplace accommodations
Because younger employees may remain enrolled in employer-sponsored plans for many years after diagnosis, these needs can meaningfully increase cumulative cost exposure if not proactively addressed.
Earlier cancer detection is a powerful lever for long-term value
As cancer care horizons extend, earlier detection becomes one of the most effective ways to moderate long‑term costs while improving outcomes. Evidence shows that diagnosing cancer just one stage earlier can reduce health care costs and significantly improve five‑year survival rates.2
Employers recognize this value. Nearly all employers surveyed report enhanced screening coverage or incentives, such as paid time off for preventive care, and some offer personalized outreach to encourage screening completion.
Screening coverage alone does not guarantee engagement
Yet gaps remain. Some employers believe that not all of their workforce is up to date on cancer screenings, highlighting a persistent disconnect between coverage and engagement.
Younger employees may not perceive themselves to be at risk, may be uncertain about screening guidelines, or may face time and access barriers. Closing this gap requires pairing coverage with targeted engagement, education, and navigation that make preventive care easier to complete.
Shifting cancer care delivery models are reshaping cost dynamics
Cancer care is increasingly outpatient, drug and specialty therapy driven. At the same time, how and where cancer care is delivered continues to evolve, with important implications for cost management.
From 2020 to 2024, cancer treatment spending shifted further toward drug-driven care. Specialty injectables share of total costs increased from 24% to 26%, while radiation therapy and surgical costs declined slightly. These trends reflect the expanding role of clinician‑administered therapies that require infusion, monitoring, and complex care coordination.
Cancer care is also increasingly delivered in outpatient settings. Over the same period, the outpatient share of total cancer care costs increased from 54% to 58%, while physician office‑based and inpatient care declined slightly. Home‑based oncology remains a small but emerging share.
Outpatient care, however, does not always mean lower cost. Provider consolidation, hospital acquisition of independent practices, and reimbursement dynamics—such as those associated with the 340B Drug Discount Program—can increase unit costs even when quality outcomes are comparable across sites of care. Evernorth analysis of more than one million oncology injectable claims3 shows fewer billing entities over time alongside rising average costs, reinforcing the importance of site‑of‑care decisions.
What employers can do now about rising cancer costs
These trends make one thing clear: rising cancer costs are not inevitable. They are shaped by decisions related to prevention, benefit design, care delivery, and site of care. Employers have meaningful opportunities to influence long‑term value by focusing on three priority actions:
- Modernize prevention and early detection.
Move beyond traditional age‑based screening models by supporting risk‑informed approaches, culturally relevant education, personalized outreach, and workplace policies that make preventive care accessible. - Deliver integrated, whole‑person cancer support.
Younger employees often need coordinated clinical, emotional, financial, and work‑related support. Integrated care models that include navigation, behavioral health, caregiver resources, and return‑to‑work planning can reduce fragmentation and downstream costs. - Adopt evidence‑based, value‑focused cost strategies.
As outpatient and infused therapies expand, employers can implement intentional site‑of‑care strategies, strengthen benefit design, and pursue value‑based payment models aligned to outcomes.
Aligning cancer strategies with a changing workforce
Cancer among younger working‑age employees reflects a fundamental shift—one that extends care horizons and increases cumulative cost exposure over time. For employers, it also presents an opportunity to modernize cancer strategies to better align with today’s workforce realities.
By focusing on early detection, whole‑person support, and value‑driven care delivery, employers can improve outcomes for employees while building more sustainable approaches to managing cancer’s long‑term impact.
For a deeper understanding of why cancer is becoming a long‑horizon condition for younger employees—and how employers can manage rising cumulative costs through early detection, integrated support, and value‑focused care—download the 2026 Health Care in Focus: Oncology report.
This article was created with the assistance of AI tools. It was reviewed, edited, and fact-checked by Evernorth’s editorial team and subject matter experts.
Evernorth Oncology Benefit ServicesSM simplifies and enhances the cancer care experience with an intelligent digital platform, a dedicated care team and access to a high-quality care ecosystem—all with a simplified, one-time payment structure for the patient. This patient-centric support is supplemented with virtual care and deep clinical pharmacy expertise from oncology specialists.
Evernorth Precision Path improves cancer care from diagnosis through survivorship by enabling earlier screening, faster treatment, and coordinated support. With 24/7 access to a multidisciplinary care team, Precision Path reduces provider burden, ER visits, and overall costs—while improving outcomes across the cancer journey.
The Evernorth Research Institute is a catalyst for change, generating industry-leading thinking that will redefine health care as we know it. Combining Evernorth’s unmatched data, analytics and health care expertise to unlock pivotal health care insights that incite action and guide meaningful progress in health care.
